Drug Profile
Firibastat - Quantum Genomics
Alternative Names: Amino butane sulfonate disulfure; QGC 001; QGC-011; RB 150Latest Information Update: 24 Jan 2023
Price :
$50
*
At a glance
- Originator CNRS; INSERM; University Paris Descartes
- Developer Quantum Genomics
- Class Amines; Aminopeptidases; Antihypertensives; Cardiovascular therapies; Disulfides; Heart failure therapies; Metalloexopeptidases; Small molecules; Sulfonic acids
- Mechanism of Action Glutamyl aminopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Hypertension
- Phase II Chronic heart failure; Left ventricular dysfunction
Most Recent Events
- 17 Jan 2023 Quantum Genomics terminates the phase III trial for Hypertension (Treatment-resistant) in USA, Slovakia, Spain, Hungary and Canada (PO) due to no efficacy demonstrated in the QGC001-3QG1 study (EudraCT2021-001404-14) (NCT04857840)
- 20 Sep 2022 Quantum Genomics completes a phase-III clinical trials in Hypertension in Bulgaria, Czech Republic, France, Germany, Hungary, Poland, Spain, USA (PO) (EudraCT2019-004509-29, NCT04277884)
- 28 Mar 2022 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in United Kingdom (PO, Tablet)